Anchyra Partners’s Edwards Lifesciences EW Stock Holding History

Anchyra Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$247K	Buy	2,859 +182	+7%	+$16.2K	0.05%	327
2026 Q2	$242K	Buy	+2,677	New	+$224K	0.06%	279

Other funds holding EW

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Anchyra Partners's EW Position: Q3 2026 in Review

Anchyra Partners increased its Edwards Lifesciences (EW) stake by 6.8% in Q3 2026, buying an estimated $16.2K and bringing the position to 2,859 shares worth $247K. The position accounts for 0.05% of the portfolio, ranked #327.

Anchyra Partners first reported a position in EW in Q2 2026 and has held it in 2 quarters since. 1,141 funds tracked by Wall St. Rank hold EW as of Q3 2026.

Anchyra Partners held 2,859 shares of Edwards Lifesciences worth $247K as of Q3 2026.
Anchyra Partners bought 182 Edwards Lifesciences shares in Q3 2026, an estimated $16.2K.
Edwards Lifesciences made up 0.05% of Anchyra Partners's portfolio in Q3 2026, its #327 holding.
Anchyra Partners first reported a position in Edwards Lifesciences in Q2 2026 and has held it in 2 quarters since.
1,141 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Anchyra Partners's 13F filing for Q3 2026, filed 13 Oct 2026.